Status:
ENROLLING_BY_INVITATION
Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)
Lead Sponsor:
Tampere University Hospital
Collaborating Sponsors:
Tampere University
European Union
Conditions:
Cervical Intraepithelial Neoplasia Grade 2/3
Adenocarcinoma in Situ
Eligibility:
FEMALE
25-25 years
Phase:
NA
Brief Summary
To identify: 1) Whether being informed infrequently results about screening is at least as a) safe and b) accurate as frequently obtaining all information from (the present combination of opportunisti...
Detailed Description
Altogether 14.000 1995-1997 born women resident in communities where herd effect against high-risk HPV infections was created with gender-neutral vaccination of birth cohorts 1992-1995 (A-communities)...
Eligibility Criteria
Inclusion
- Born 1995-1997. 25 years of age residence in one of the eight community-randomized trial A communities with documented herd effect from gender-neutral vaccination or C communities devoid of the herd effect.
Exclusion
- Immune compromising disease status (e.g. transplant recipients). HPV vaccination
Key Trial Info
Start Date :
June 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
14000 Patients enrolled
Trial Details
Trial ID
NCT04755517
Start Date
June 9 2020
End Date
December 31 2025
Last Update
January 13 2025
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
HPV-tutkimukset
Hämeenlinna, Finland, 40100
2
HUS
Helsinki, Finland
3
HPV-tutkimukset
Iisalmi, Finland, 74100
4
HPV-tutkimukset
Joensuu, Finland, 80100